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INTRODUCTION 
 
Since the first available report of AlP poisoning in the early 1980s 
from India, it is now one of the most common cause of poisoning among 
agricultural pesticides. Unfortunately the absence of a specific antidote 
results in very high mortality and the key to treatment lies in rapid 
decontamination and institution of resuscitative measures. AlP also poses 
as a threat for chemical terrorism due to the immediate release of lethal 
phosphine gas. Previously, the laws and legislations were not that strict 
and it was easily available on the counter; but in the last few years stricter 
norms have reduced its easy availability, even though they are still not 
enough to reduce the suicidal rate due to its consumption, which 
traumatizes so many families 
         Phosphides are used throughout the world as pesticides to protect 
stored grains from rodents and pests. In India ,especially in south india, 
aluminium phosphide (AlP) is accessible as 3-g tablets that are a 
combination of 56% AlP (total dose of 1,680 mg) and 44% ammonium 
carbonate. In the past 35 years, high mortality rates have been reported 
following significant exposures to aluminium, zinc or calcium 
phosphides. Exposure is rarely accidental with the majority of cases 
involving intentional acts of suicides. After ingestion, solid phosphide 
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including AlPs produce a toxic phosphine gas following any contact with 
water, moisture in the air, or hydrochloric acid in the stomach. Although 
the exact mechanism has not been well defined, it has been demonstrated 
that phosphine acts at the mitochondrial level, and once systematically 
absorbed, it will interfere with synthesis of enzymes and proteins. In 
addition to the corrosive action of phosphine, the mechanism of toxicity 
includes formation of highly reactive hydroxyl radicals. Cellular injury 
due to lipid peroxidation is also suggested. Previously, a reduction in the 
level of catalase and rise in the activity of superoxide dismutase in 
patients of AlP poisoning have been reported. The reduction of 
glutathione concentration in different tissues in AlP poisoning also 
explains the cellular injury, as glutathione is a protecting factor against 
oxidation by catalyzing the reduction of the oxygen peroxide in O2 and 
H2O.  
Indicators of oxidative stress (reduced glutathione and 
malondialdehyde) are showed to reach peak levels within 48 h of 
exposure to poison. To our knowledge, there is paucity of data regarding 
measurement of total antioxidant capacity in patients with AlP poisoning 
although presence of phosphine-induced oxidative damage in animal 
studies has been well established. Moreover, any decrease in plasma 
levels of thiol groups, as an important part of antioxidant defense system, 
might imply the presence of oxidative stress in an AlP-poisoned patient. 
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This might result in generation of free radical and alteration in 
antioxidant system. Hence, this study was conducted to evaluate the 
existence of prognostic significance of High Blood Sugar Value in acute 
aluminium poisoning on admission. 
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AIM AND OBJECTIVES 
         The main goal of this study was to evaluate the prognostic 
significance of High Blood Sugar Value in acute aluminium poisoning on 
admission. 
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REVIEW OF LITERATURE 
Phosphine (PH3) was discovered in the late 1700s and has been 
used as a grain fumigant since the 1930s. It is by far the dominant means 
of controlling pest insects in stored grain and many other stored 
commodities 
 Aluminium phosphide (AIP), a solid fumigant pesticide is widely 
used in India for grain preservation at homes and in warehouses 
Aluminium phosphide (aluminum phosphide) is a highly toxic 
inorganic compound with the chemical formula AlP used as a wide band 
gap semiconductor and a fumigant. This colorless solid is generally sold 
as a grey-green-yellow powder due to the presence of impurities arising 
from hydrolysis and oxidation.  
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Properties 
 
AlP crystals are dark grey to dark yellow in color and have a 
zincblende crystal structure with a lattice constant of 5.4510 Å at 300 K. 
They are thermodynamically stable up to 1,000 °C (1,830 °F). 
Aluminium phosphide reacts with water or acids to release 
phosphine: 
 AlP + 3 H2O → Al(OH)3 + PH3 AlP + 3 H+ → Al3+ + PH3 
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Preparation 
AlP is synthesized by combination of the elements: 
4Al + P4 → 4AlP  
Caution must be taken to avoid exposing the AlP to any sources of 
moisture, as this generates toxic phosphine gas.  
Other names are Aluminum phosphide, Aluminium(III) phosphide, 
Aluminium mono phosphide ,Phostoxin, Fumitoxin. 
Uses 
 Pesticide 
AlP is used as a rodenticide, insecticide, and fumigant for stored 
cereal grains. It is used to kill small verminous mammals such as moles 
and rodents. The tablets or pellets, known as "wheat pills", typically also 
contain other chemicals that evolve ammonia which helps to reduce the 
potential for spontaneous ignition or explosion of the phosphine gas AlP 
is used as both a fumigant and an oral pesticide. As a rodenticide, 
aluminium phosphide pellets are provided as a mixture with food for 
consumption by the rodents. The acid in the digestive system of the 
rodent reacts with the phosphide to generate the toxic phosphine gas. 
Other pesticides similar to aluminium phosphide are zinc phosphide and 
calcium phosphide. 
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In this application, aluminium phosphide (Alp) is marketed in India 
under various trade names Alphos, Bidphos, Celphos,Fostox, Chemfume, 
Delicia, Fumigran, Phosphotek, Phosphume, Phostoxin, Quickphos, 
Synfume, Fumitoxin, Phostek , Phostoxin, Quick Phos, Talunex, 
Fieldphos, and Weevil-Cide. It generates phosphine gas according to the 
following hydrolysis equation.  
Aluminium phosphide is said to be the most ideal grain 
preservative since it is relatively cheap while being very effective in 
repelling pests. The required number of tablets are removed from the 
airtight container and placed among the grain. On exposure to moisture, 
phosphine is released which percolates among the grain. When fumigated 
grains are subsequently well aerated, phosphine evaporates rapidly 
leaving behind virtually no residue. Traces of phosphite and 
hypophosphite of aluminium may be present, but they are non-toxic 
 2 AlP + 6 H2O → Al2O3·3 H2O + 2 PH3  
It is used as a fumigant when other pesticide applications are 
impractical and when structures and installations are being treated, such 
as in ships, aircraft, and grain silos. All of these structures can be 
effectively sealed or enclosed in a gastight membrane, thereby containing 
and concentrating the phosphine fumes. Fumigants are also applied 
directly to rodent burrows. 
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Semiconductor applications 
Industrially, AlP is a semiconductor material that is usually alloyed 
with other binary materials for applications in devices such as 
lightemitting diodes (e.g. aluminium gallium indium phosphide). 
It is generally available as greyish green tablets of 3 grams each, 
mixed with urea and ammonium carbonate. These tablets are sold in 
sealed, airtight containers of tens and twenties. Each tablet liberates 1 
gram of phosphine. 
 It protects the stored grain from pests, insects and rodents by 
liberating toxic phosphine (PH3) gas after coming in contact with 
moisture.  
Each tablet/packet contains 56% of AIP and 44% of ammonium 
carbonate [(NH4)2 CO3] as active ingredients; is able to liberate PH3 by 
one-third of its weight. Phosphine, being a gas, diffuses uniformly 
throughout the grains and the residues such as phosphite and 
hypophosphite of aluminium are left in the packet/grains which are 
nontoxic. 
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The poisoning is generally suicidal, rarely homicidal and 
occasionally accidental (children) and is common in younger age groups. 
MODE OF ACTION OF PHOSPHINE  
            Its toxic effects are due to the liberation of PH3 in the stomach 
after ingestion of AIP. Inhalation toxicity (inhalation of PH3) is 
uncommon and primarily involves lungs.  
Fumigation has also caused unintentional deaths, such as examples 
in Saudi Arabia, and the United States  Known as "rice tablet" in Iran, for 
its use to preserve rice, there have been frequent incidents of accidental or 
intentional death. There is a campaign by the Iranian Forensic Medicine 
Organization to stop its use as a pesticide. 
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Recycling of used aluminium phosphide containers caused the 
death of three family members in Alcalá de Guadaira, Spain. They had 
been keeping them in plastic sacks in their bathroom. The deaths occurred 
accidentally due to aluminum phosphide reacting with water or moisture, 
and becoming phosphine, leading to their death within hours. 
         The other gases liberated in addition to PH3 include ammonia and 
CO2 which provide an inert media for PH3 to act: 
 
 AIP + 3HCI → AICI3 + PH3↑  
AIP + 3H2O (moisture) → AI(OH)3 + PH3↑  
(NH4)2CO3 + H2O→2NH3 ↑+ CO2 ↑+ 2H2O  
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In one study Basic serum biochemical parameters, activity of 
mitochondrial complexes, antioxidant enzymes and parameters of 
oxidative stress were estimated in the platelets of patients who developed 
severe poisoning following ALP ingestion. These parameters were 
compared with healthy controls and with patients with shock due to other 
causes like cardiogenic shock, septic shock and hemorrhagic shock . The 
serum levels of creatine kinase-muscle brain and lactate dehydrogenase 
were higher in patients poisoned with ALP, whereas a significant 
decrease was observed in the activities of mitochondrial complexes I, II 
and IV. The activity of catalase was lower but the activities of superoxide 
dismutase and glutathione peroxidase were unaffected in them. A 
significant increase in lipid peroxidation and protein carbonylation was 
observed, whereas total blood thiol levels were lower. In patients severely 
poisoned with ALP, not only cytochrome c oxidase but also other 
complexes are involved in mitochondrial electron transport, and enzymes 
are also inhibited           
The exact mode of action of PH3 is not known. It has been claimed 
to inhibit cytochrome c oxidase, a respiratory chain enzyme, similar to 
cyanide.  
16 
 
 
The effects of phosphine on electron transport and on some partial 
reactions of oxidative phosphorylation of mitochondria from mouse liver, 
housefly flight muscles and granary weevils has been studied. Phosphine 
was a strong inhibitor of respiration of mitochondria in the “active” state 
(state 3), uncoupled state, and ion-pumping state on glutamate, pyruvate 
plus malate, succinate, α-glycerophosphate, and ascorbate-
cytochrome c as substrates. Respiration of mitochondria in state 3 was 
completely inhibited by about 250 μM phosphine. By contrast, the 
respiration of mitochondria in state 4 was much less sensitive.  
This inhibition could not be released by uncouplers suggesting that 
it is due to a direct effect on electron transport. Only site III was inhibited 
to any significant extent. Kinetic studies show that the inhibition was 
noncompetitive with Ki ranging from 1.6×10
−5
 to 7.2×10
−5
 depending on 
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the source and purity of cytochrome oxidase. The inhibition of site III 
was also more pronounced in sonicated particles than in intact 
mitochrondria. The significance of this is discussed in relation to 
membrane sideness and topology of the components of the respiratory 
chain. 
Phosphine was unable to activate the “latent” ATPase nor did it 
have any inhibition of the Mg
2+
-simulated ATPase and only high levels 
(1.1 mM) showed modest inhibition (41%) of uncoupler-stimulated 
ATPase. Phosphine had no effect on the ATP-Pi exchange and on the 
ATP-ADP exchange reaction at concentrations causing strong respiratory 
inhibition. 
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A schematic representation of the mitochondrial respiratory chain, 
ROS formation, and phosphine toxicity. The respiratory chain consists of 
specialized metal heme complexes such as complexes II, III, IV, and an 
ATP synthase known as complex V. Complex I, ubiquinone, cytochrome 
c, proton pumps, membrane potential, and proton motive force are critical 
parts of electron flow in the respiratory chain. Oxidative phosphorylation 
is carried out in the inner membrane by respiratory assemblies. From 
these assemblies, two electrons from NADH are transferred to O2 by a 
series of electron carriers, starting with NADH dehydrogenase. Electrons 
are transferred to the ubiquinone (also known as coenzyme Q (CoQ)) and 
then to the cytochrome a group of hemeproteins. There are five 
cytochromes between CoQ and molecular O2: cytochromes b, c1, c, a, 
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and a3. Cytochromes a and a3 are also known as cytochrome oxidase. 
The production of ATP occurs at 3 sites: (1) between NADH and CoQ, 
(2) between cytochromes b and c, and (3) between cytochrome c and O2. 
The inner membrane is impermeable to most molecules because of its 
high proportion of phospholipids and cardiolipin. Transport proteins 
embedded in the inner membrane selectively incorporate metabolites into 
the matrix and export ATP for biological processes. 
 The matrix is the site of high energy–yielding reactions from the 
metabolism of pyruvate and fatty acids derived from carbohydrates and 
other nutrients. Pyruvate and fatty acids that are transported into the 
matrix help to generate a pair of electrons that have a high energy transfer 
potential. These are carried by NADH and FADH2 (flavin adenine 
dinucleotide reduced form), which are formed in glycolysis, fatty acid 
oxidation, and the citric acid cycle. The released high energy from this 
reaction is used to produce ATP through oxidative phosphorylation, 
which is a major metabolic reaction in aerobic organisms. Oxidative 
phosphorylation is strongly coupled to fatty acid oxidation, which forms 
acetyl CoA and the citric acid cycle to produce the energy needed for 
aerobic cell metabolism. Respiratory assemblies are an integral part of the 
inner membrane, whereas fatty acid oxidation and the citric acid cycle 
activity occur in the matrix. Flow of electrons causes an electrochemical 
proton gradient under the control of the proton motive force for the 
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production of ATP. During active respiration, mitochondria produce a 
proton motive force across the inner membrane. This results in a negative 
charge inside, thereby producing a pH gradient. Electron leakage from the 
respiratory chain from enhanced ROS production causes additional 
oxidative insult. If active electron flow ceases through the respiratory 
chain, proton motive force collapses and ATP production discontinues. 
This causes loss of membrane potential and release of additional ROS. 
The dashed arrows indicate the putative inhibition of critical components 
of the respiratory electron transport chain by phosphine. 
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             Interaction of phosphine with enzymes involved in metabolic 
processes and acetylcholine signalling.  
        Sites of interaction with arsenite and nitric oxide (NO) are also 
shown: phosphine (green), arsenite (dark blue), and nitric oxide (light 
blue).  
         Sites of ROS generation (red) are indicated as well. The cross 
behind the names of targeted enzymes indicates that they are inhibited. 
The potassium and calcium currents are regulated by acetylcholine via 
NO. Ca
2+
 triggers the release of acetylcholine from vesicles in the 
cytoplasm into the neuronal synapse.  
        The acetylcholinesterase degrades acetylcholine, which reduces the 
strength of neurotransmission. The net effect is that arsenite and 
phosphine increase acetylcholine signalling by inhibiting the esterase.        
         FAD/FADH2 (Flavin adenine dinucleotide oxidised/reduced), 
NAD
+
/NADH (nicotinamide adenine dinucleotide oxidised/reduced), 
ADP/ATP (adenosine di/tri nucleotide), NO (nitric oxide), ROS (reactive 
oxygen species), and TCA (tricarboxylic acid). 
            Some workers have claimed inhibition of mitochondrial catalase 
enzyme, extramitochondrial release of hydrogen peroxide (H2O2) and 
generation of oxygen free radicals by phosphine (PH3). Free radicals 
23 
 
seem to play a role in the initiation and propagation of cell damage, in 
addition to the direct toxic effects of phosphine. 
 
Free radicals scavengers superoxide dismuatase (SOD) and 
catalase and lipid peroxidation were studied in  patients of aluminium 
phosphide poisoning irrespective of age and sex admitted to a hospital in 
north India. Serial serum superoxide dismutase (SOD), catalase and 
MDA (malonyldialdehyde) were estimated on days 1, 2 and 5 post-
admission depending on the survival of the patients. Serum SOD levels 
were significantly higher but serum catalase was significantly lower in 
patients than controls.On days 1 and 2 which suggested stimulation of 
SOD and inhibition of catalase by phosphine resulting in excessive 
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hydrogen peroxide (H2O2) load. Significantly higher levels of MDA  in 
patients than controls on days 1 and 2 indicated enhanced lipid 
peroxidation in this poisoning. The significantly high levels of SOD and 
MDA in non-survivors suggested their direct relation to mortality while 
catalase levels had an inverse relationship. Return of SOD and catalase 
and MDA to normal or near normal levels in survivors by day 5 
suggested abolition of an oxidative stress due to elimination of 
phosphine.  
Most of the toxic effects of metal phosphides are owed to PH3, 
which is a protoplasmic poison that interferes with the function of the 
cellular enzymes and proteins. According to some authors, the 
mechanism of its toxicity is electron transfer blockage and non-
competitive blockage of cytochrome C oxidase, which inhibits oxidative 
phosphorylation and, in turn, cellular respiration and activation of 
peroxide radicals.  
Phosphine can inhibit catalase and deplete glutathione, which may 
result in cellular wall and canal dysfunction as well. According to 
Proudfoot, studies have shown that phosphine impairs cellular respiration. 
It inhibits the entrance of amino acids into the cycle of myocardial protein 
synthesis and also inhibits cytochrome C oxidase in cardiac cells. 
According to Anand et al, these changes in the mitochondria and 
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myocardial proteins impair cellular permeability to sodium, potassium, 
magnesium, calcium, and other ions and change cardiac cell wall 
potential.  
Phosphine-induced pathophysiological changes are more 
prominent in the myocardium, pulmonary cells, and tiny peripheral 
vessels. Both AlP and phosphine inhibit cholinesterase, but this inhibition 
is unlikely to be clinically relevant. Another toxic action of phosphine is 
that it changes the capacity of haeme. In vitro studies show that humans 
and rats can absorb unhydrolysed aluminium phosphide salt, which keeps 
reacting with free haemoglobin and haemoglobin in normal red blood 
cells (RBCs) to produce haemichrome, a derivative of methaemoglobin. 
Levels of carbon monoxide, which can be established by CO-oximetry, 
can help diagnosis and prognosis of AlP poisoning. Namely, phosphine 
may affect oxyhaemoglobin that interacts with CO and cause 
dyshaemoglobinemia, which can yield high CO findings. Considering 
that phosphine produces free oxygen radicals in body tissues, it has been 
shown that organs with a higher need for oxygen (heart, lung, kidney, and 
liver) are more sensitive to the damage induced by phosphine gas, which 
is compatible with the post-mortem histopathological changes in these 
organs. In addition, Heinz bodies, which are indicative of the destruction 
of haemoglobin in vitro, increase to 1.25 µg mL-1 in poisoned patients. 
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Occupational and environmental phosphine exposure Occupational 
exposures to phosphine are uncommon and rarely severe (Sudakin, 2005) 
but accidental inhalation is a particular risk to those in close proximity to 
grain that has had a metal phosphide mixed in with it.  
Recurring locations include ships holds (Gregorakos, et al, 2002, 
Hansen & Pedersen, 2001, Vohra, et al, 2006), Rail wagons (Perotta, et al 
1994, Vohra, et al, 2006),  Grain elevators (Abder-Rahman, et al, 2000), 
Grain stores (Brautbar & Howard, 2002, Misra, et al, 1988), and even 
stores in homes (Abder-Rahman, et al, 2000). 
 Potentially lethal concentrations of the gas may develop in the 
head-spaces of unventilated or poorly ventilated storage containers and 
domestic premises (Memis, et al, 2007).  
Phosphine may be released during the illicit manufacture of 
methamphetamine (Burgess, 2001, Willers-Russo,1999); deaths have 
resulted (Willers-Russo, 1999). 
 In another incident, a packet of aluminium phosphide in a 
container from abroad burst open and the sweepings placed in water 
causing immediate fizzing and liberation of phosphine (Kamanyire & 
Murray, 2003). 
 Close proximity to a source of phosphine is not required to be at 
risk of toxicity as phosphine gas can travel some distance as it is heavier 
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than air (vapor density 1.2:1). Many years ago 12 individuals in a house 
adjacent to a warehouse used to store aluminium phosphide developed 
vomiting and one died. The illnesses were attributed to phosphine (Glass, 
1959).  
More recently exposures have been alleged after use of metal 
phosphides to control pests in adjacent buildings 
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 The above mechanisms may explain the fact that hyperglycemia is 
a poor prognostic factor in aluminium phosphide poisoning. 
 The administration of Hyperinsulinemia euglycemia therapy has an 
advantage in improving mortality in AlP posoining. 
 It improves inotropy and peripheral vascular resistance and reverse 
acidosis by improving myocyte carbohydrate uptakeand utilisation. 
 Thus, oxidative stress can be possibly ameliorated by management 
of hyperglycemia and changes or disruptions in these mechanisms 
may reduce the risk of insulin resistance and the development of 
hyperglycemia and, furthermore, may have a potential role in its 
treatment 
 
29 
 
CLINICAL TOXICITY 
 Forensic Issues Prior to 1980, aluminium phosphide poisoning 
was virtually unreported in India. Today it is the leading cause of suicidal 
(and sometimes accidental) death in northern Indian states such as 
Punjab, Haryana, Uttar Pradesh, Madhya Pradesh, and Rajasthan. 
Southern states have so far not been significantly affected since 
aluminium phosphide is yet to make inroads into the agricultural sector 
here. But there are ominous indications of a gradual rise in the number of 
cases being reported 
The toxic dose of oral AIP compound is 500 mg/70 kg in humans. 
Toxicity occurs either due to suicidal ingestion of AIP or inhalation of 
liberated PH3 from fumigated grains. The lethal dose of AlP in a normal 
70-kg adult has been reported to be 500 mg. In the work place, air 
phosphine level of 50 mg L-1 (50 ppm) may be dangerous for health, and 
400-600 mg L-1 (400-600 ppm) may cause death in 30 minutes. 
Lethal dose or concentration (LD, LC): LD50 (median dose) 11.5 
mg/kg. 
Phosphine is widely absorbed and distributed in the tissues. It is 
also known that AIP is absorbed as such and possibly deposited in liver 
leading to slow release of PH3 which may be responsible for extended 
poisoning in humans. 
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 The signs and symptoms of acute, moderate-to-severe ingestional 
poisoning appear within 45 minutes to one hour. The organs involved 
include gastrointestinal tract, heart, lungs, liver, kidneys and the brain. 
Inhalational toxicity is invariably accidental; occurs in persons 
sleeping in warehouses where stored grains are fumigated with AIP.  
An exposure to high PH3 concentration leads to shock or 
cardiovascular collapse but a lower concentration produces pulmonary 
oedema.  
However, the lower concentration (7.5 mg/m3) may cause cough, 
dyspnoea and mild respiratory failure. 
CLINICAL FEATURES 
Aluminium phosphate poisoning affects the most organs and a 
variety of signs and symptoms appear in patients. Early symptoms 
include nausea, vomiting, retrosternal and epigastric pain, dyspnea, 
anxious, agitation and smell of garlic  on the breath. 
 Moreover shock and peripheral circulatory failure are mainly 
imperative early signs of toxicity. Mortalities in past studies have ranged 
from 40–77% and in one survey 55% occurred within 12 h of ingestion 
and 91% within 24 h. 
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CARDIAC TOXICITY 
 Cardiac toxicity comprises circulatory failure ,hypotension, 
congestion of the heart, separation of myocardial fibres by edema, 
fragmentation of fibres, non-specifc vacuolation of myocytes, focal 
necrosis, neutrophil and eosinophil infiltration were found in autopsy . 
Also, significantly increasing left ventricular dimensions , hypokinesia of 
the left ventricle and septum, akinesia, ejection fractions reduction , 
severe hypotension, raised systemic venous pressure, normal pulmonary 
artery wedge pressure, inadequate systemic vasoconstriction and ECG 
abnormalities are sinus tachycardia, sinus arrhythmia with ST segment 
depression in lead II, III, and AVF, ST elevation, atrial fibrillation, T 
wave inversion in V5-6, sinus arrest, chaotic atrial pacemaker, complete 
heart block, bundle branch block, and ventricular premature complexes 
followed by ventricular tachycardia. Massive focal myocardial injury 
with elev ated serum levels of cardiac enzymes may occur. 
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RESPIROTORY TOXICITY 
 Tachypnea, dyspnea, crepitations, and rhonchi were present on 
examination of phosphide poisoning. Respiratory distress is invariably 
present with cyanosis, and cold, clammy skin. Pulmonary edema is 
common but it is not always clear whether it is cardiogenic or non-
cardiogenic in etiology. It tends to develop 4–48 h after ingestion and the 
finding of a reduced arterial pressure of O2 without an increase in 
pulmonary artery wedge pressure, suggested it was non-cardiogenic. 
Others have confidently diagnosed adult respiratory distress syndrome  
and non-specific pulmonary edema and the edema fluid may be protein-
rich and hemorrhagic.Type 1 and Type 2 respiratory failure may occur. 
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GASTROINTESTINAL TOXICITY 
 Hematemesis , corrosive lesions of the esophagus and stomach , 
vomiting, epigastric pain, severe gastric erosions, duodenal erosions, 
esophageal strictures tracheo-oesophageal fistulae,dysphagia.  Dysphagia 
may be apparent as soon as 3 or 4 days after ingestion of aluminium 
phosphide but is more usual about 2 weeks later. 
In some rare presentations diarrhoea may occur. 
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HEPATIC TOXICITY  
Transient elevations of alanine aminotransferase and aspartate 
aminotransferase activities are not infrequent after ingestion of metal 
phosphides) but jaundice secondary to liver damage is much less 
common. Jaundice was alleged to be present in members of the crew of a 
grain freighter who inhaled phosphine after an accidental release.Serum 
bilirubin concentrations were normal and transaminase activities only 
minimally disturbed. Acute hepatic failure and encephalopathy was 
considered to be the cause of death insome patients. a 12-yearold girl died 
from a combination of acute hepatic failure and encephalopathy with 
renal failure shows in the study of Bayazit, et al. Portal edema, 
congestion of the portal tract and central veins, and vacuolization of 
hepatocytes are the most frequent findings at autopsy. 
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ELECTROLYTE AND METABOLIC ABNORMALITIES  
Hypokalemia, metabolic acidosis, mixed metabolic acidosis and 
respiratory alkalosis, and acute renal failure are reported frequently. 
Also,hyperglycemia and Hypoglycemia and hypomagnesemia have been 
reported in several studies.  
Hypokalemia is common soon after ingestion of metal phosphides 
and is probably secondary to vomiting, though catecholamine release 
could also contribute. It is thought to be the result of impaired 
gluconeogenesis and glycogenolysis  possibly secondary to adrenal gland 
damage and low circulating cortisol concentrations. Hyperglycemia 
reported in study of Abder-Rahman, 1999 and it appears to be rare. The 
main controversy relates to the existence or otherwise of disturbances of 
magnesium homeostasis. In 1989, prompted by reports of the empirical 
use of magnesium sulphate to treat phosphide toxicity, this study 
demonstrated that serum magnesium concentrations were increased, 
possibly secondary to release from damaged cardiac myocytes and 
hepatocytes, and confirmed the findings in subsequent studies. 
Unfortunately, other studies have found the converse, that is serum and 
erythrocyte concentrations were reduced rather than increased. Compared 
serial serum and erythrocyte magnesium concentrations in four groups of 
people. One comprised patients poisoned with aluminium phosphide who 
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had resulting shock and cardiotoxicity while the second included those 
poisoned but without shock or cardiac features. The remaining two 
groups acted as controls, the first being patients in shock secondary to 
trauma or hemorrhage but without other features of cardiac toxicity and 
the second, normal volunteers. The only significant finding in admission 
samples was that cell and serum concentrations were lower in shocked, 
cardiotoxic patients. 
 Hypomagnesemia was found in toxic shocked patients but not in 
those with non-toxic shock and secondly, 75% of those in the toxic/shock 
group had ECG changes, it was concluded that the evidence supported a 
causal relationship between hypomagnesemia and phosphide induced 
shock. Without intervention both serum and cell values returned to 
normal by about 24 h,and thought the hypomagnesemia secondary to 
consumption in combating free radical stress. Hypomagnesemia has also 
been found in a recent single case of phosphine inhalation from 
aluminium phosphide. They found pre-treatment mean serum and red cell 
magnesium concentrations to be normal. Concentrations were increased 
in the brains, lungs, hearts, livers, kidneys, and stomachs of fatalities but 
later studies showed this to be the result of magnesium administration and 
not phosphide toxicity. Clearly, these studies cannot all be correct and the 
analytical method used to generate the results may be an important factor. 
The results of a study (Siwach, et al, 1994) carry particular weight 
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because they used atomic absorption spectroscopy, a technique that is 
superior to the colorimetric method published in 1977 and used and the 
titan yellow method employed. Eventhough the results obtained using the 
former method correlated extremely well with those from atomic 
absorption spectroscopy there is no choice but to accept that neither 
hypomagnesemia nor hypermagnesemia is a feature of aluminium 
phosphide poisoning. 
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HEMATOLOGICAL TOXICITY 
Although phosphine causes Heinz body formulation and 
hemoglobin oxidation in vitro, intravascular hemolysis and 
methemoglobinaemia are unusual complications of phosphide poisoning 
in humans. Nine patients with intravascular hemolysis after ingestion of 
aluminium phosphide have been identified from the pervious studies.  
Glucose-6-phosphate dehydrogenase deficient, including one 
young man who had previously developed haemolysis when given 
primaquine. Intravascular hemolysis was associated with renal failure and 
severe metabolic acidosis to which 3 days of vomiting and diarrhea may 
have partly contributed. In addition to hemolysis some patients found to 
have methemoglobinaemia of 17% 32 h post-ingestion while another 
developed Heinz bodies, a further indicator of damage to hemoglobin.  
Rats given aluminium phosphide had methemoglobin 
concentrations measured at 10 and 30 min intervals. They increased 
simultaneously with those of malonyldialdehyde suggesting that 
methemoglobinaemia was secondary to increased oxygen free radical 
generation. 
 A study revealed that there is a significant association between 
blood level of methemoglobin and mortality in patients with aluminium 
phosphide intoxication. 
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 Disseminated intravascular coagulation was present patients 
poisoned with aluminium phosphide. 
UNCOMMON FEATURES 
Unusual complications of phosphide ingestion include atrial 
infarction,Bleeding diathesis, adrenocortical congestion, hemorrhage and 
necrosis, pancreatitis, and renal failure. Acute pericarditis has also been 
reported infrequently though pericardial fluid was detected by 
echocardiography in a  patients in one study. Subendocardial infarction 
complicated the recovery of a 16-year-old male and a 26-year-old woman 
who had recovered from aluminium phosphide ingestion reported in some 
studies. Some patients suffered an intracranial hemorrhage 5 days after 
the event. No explanation other than the poison was found in that patient. 
Convulsions have been reported in some cases. Coma supervenes in later 
stages. 
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INVESTIGATIONS  
1. Blood sugar value at the time of admission 
2. Complete haemogram  
3. Blood biochemistry, e.g. urea, sugar, creatinine, transaminases, 
bilirubin, electrolytes, etc.  
4. Electrocardiogram (ECG) for arrhythmias, myocarditis and 
conduction defects.  
5. Chest radiograph (posteroanterior view) for acute respiratory 
distress syndrome (ARDS), aspiration pneumonia, etc. 
6. Blood gas analysis for hypoxia and acidosis  
7. Serum magnesium levels 
8. Toxicologic screening, e.g. blood phosphine levels. 
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DIAGNOSIS 
1. Garlicky odour in the breath.  
2. Urinalysis may reveal occult blood, bilirubin, glucose, and albumin.  
3. Liver function tests are often abnormal. 
4. Blood urea and serum creatinine are usually higher than normal.  
5. Hypo/hypermagnesaemia; hypo/hyperphosphataemia. 
6. ECG changes (mentioned under Clinical Features).  
Qualitative tests for detecting phosphine in the breath and gastric 
aspirate:  
a. Breath test: A piece of filter paper impregnated with 0.1 N silver 
nitrate solution is used in the form of a mask through which the 
patient is asked to breathe in and out for 5 to 10 minutes. 
Blackening of the paper is indicative of the presence of phosphine 
in the breath, since silver nitrate is reduced to silver on exposure to 
it. Similar reaction is also produced by hydrogen sulfide. 
b. Biological sample test: A small amount of gastric apirate (5 to 10 
ml) or minced tissue (5 to 10 gm of liver)* is taken into a steam 
distillation flask to which an equal quantity of water is added and 
then acidified with dilute HCl or H2SO4, followed by heating upto 
500C for 15 minutes. The distillate is collected in an ice cold 
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receiver containing 5 ml of 1% silver nitrate solution by dipping 
the adapter into it. If phosphine is present, the solution will turn 
black.          
i. For confirmation, add 5 ml of concentrate.HNO3 to the black 
precipitate and boil till the solution becomes clear. Then add 5 
ml of ammonium molybdate solution and heat for a minute. 
Formation of a yellow precipitate confirms the presence of 
phosphine.  
ii.  A variation of this test involves placing 0.1 N lead acetate filter 
paper over the mouth of the distillation flask containing the 
sample (prepared in the same manner as detailed above). The 
flask is heated for 15 minutes at 50oC. Phosphine will blacken 
the silver nitrate paper, while hydrogen sulfide will blacken 
both papers. 
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Nil toxicity means ingestion of exposed compound (tablets kept out 
of containers or powder in open packets) which does not produce any 
systemic manifestation except local symptoms such as nausea, vomiting 
or retrosternal burning. Prognosis is excellent.  
Mild ingestional toxicity is diagnosed by the history of taking a 
small dose of partially exposed compound (broken tablet/ exposed 
packet/non-smelling tablet). There is a slight drop in blood pressure with 
nausea, vomiting, retrosternal burning or pain. Arrhythmias are 
occasional and metabolic acidosis is rare. AgNO3 test is negative. Most 
of these patients survive. 
 All types of cardiac arrhythmias (brady- or tachy-arrhythmias) 
have been observed either alone or in combination with other ECG 
changes in 40% to 80% patients with moderate-to-severe poisoning. The 
ST segment elevation/depression due to acute myocarditis is also 
observed commonly (30%). The conduction disturbances (sinoatrial, 
atrio-ventricular, bundle branch blocks, intra-ventricular conduction 
delay, etc) are least common, occurring in 5% to 10% patients. 
There may be hypoxaemia (PaO2 <60 mmHg) and metabolic 
acidosis (pH <7.1) in 75% to 80% cases. Magnesium levels have been 
found to be low or normal. Hypokalaemia,hyperlycemia or 
hypoglycaemia has been observed.  
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  Sometimes, patients may not divulge the history of AIP ingestion. 
In such a situation, a high degree of suspicion combined with sudden 
onset of unexplained shock or cardiac arrhythmias and blood samples, if 
appear too dark to explain, form important clues to the diagnosis of this 
poisoning in younger patients. 
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MANAGEMENT 
 
    The early recognition and management is essential to reduce 
mortality. 
     The main goal of therapy is to sustain life till PH3 gets excreted. 
Steps to Remove as well as to Retard PH3 Absorption. 
 
 
 
 
 
 
 
 
 
 
 
46 
 
DECONTAMINATION  
Gastric lavage is probably best avoided after ingestion of 
phosphides as it might increase the rate of disintegration of the pesticide 
and increase toxicity. To reduce the absorption of phosphine, gastric 
lavage with potassium permanganate (1:10,000) is done. Permanganate is 
used as it oxidizes PH3 to form non-toxic phosphate. This is followed by 
a slurry of activated charcoal (approximately 100 gm) given through a 
nasogastric tube. In vitro studies suggested that vegetable oil and liquid 
paraffin inhibit phosphine release from phosphides but these oils have not 
been tested in clinical practice. However, vomiting may make the 
administration of charcoal difficult. Although the administration of 
sodium bicarbonate via a gastric tube to decrease gastric hydrochloric 
acid has been proposed in the belief that hydrochloric acid assists the 
conversion of phosphide to phosphine, there is no experimental support 
for its use. Moreover, based on an understanding of the mechanisms of 
toxicity of metal phosphides, this strategy is unlikely to reduce morbidity 
and mortality. Removal of victims of phosphine inhalation from the 
contaminated atmosphere will have been carried out by the emergency 
service first on scene. Supplemental oxygen may be given if necessary 
but further measures for airway control are unlikely to be required 
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    Judicious use of antacids (60 mL/hour) to reduce gastric 
symptoms and to reduce PH3 absorption. In addition, if needed H2-
blockers may be given as intravenous infusions.  
STEPS TO REDUCE TISSUE TOXICITY 
 There is no specific antidote to phosphine.  
Magnesium sulphate possesses membrane stablising properties and 
has been used in several studies from India.       
  The effective dose schedule is to start with 1 g IV, then 1 g IV 
after one hour for 3 consecutive hours, then 1 g IV infusion after 4 to 6 
hours for 3 to 5 days. It can reverse some arrhythmias and mortality is 
reduced. 
   Phosphine is a stable, partially water soluble gas and is excreted 
to some extent in the urine but is mainly excreted through breath; hence, 
adequate hydration and renal perfusion by IV fluids and low-dose 
dopamine 2 to 4 µg/kg/min must be maintained to allow its renal 
excretion.  
  Diuretics are not useful in the presence of shock. Patients with 
severe poisoning are haemodynamically unstable but maintain a good 
urine output, hence, dialysis is usually not done. If acute renal failure 
develops and patient is haemodynamically stable, then dialysis may be 
useful. 
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SUPPORTIVE MEASURES 
Many patients will die from metal phosphide poisoning despite 
intensive care. Supportive measures are all that can be offered and should 
be implemented as required by clinical developments. The most 
important factor for success is resuscitation of shock and institution of 
supportive measures as soon as possible. Intravenous access should be 
established and 23 litres of normal saline are administered within the first 
8-12 hr guided by central venous pressure (CVP) and pulmonary capillary 
wedge pressure (PCWP). The aim is to keep the CVP at around 12-14 cm 
of water Some workers have recommended rapid infusion of saline (3-6 
litres) in the initial 3 hr . 
 Low dose dopamine (4-6 μg/kg/min) is given to keep systolic 
blood pressure >90 mm Hg. The other vasopressures such as 
norepinephrine may be usefull in critical patients. The use of high doses 
of glucagon may benefit in the treatment of aluminum phosphide 
poisoning; the likely mechanism of action is the increase of cAMP in the 
myocardium, effectively bypassing the β-adrenergic second messenger 
system. Oxygen is given for hypoxia. Acute respiratory distress syndrom 
requires intensive care monitoring and mechanical ventilation.  
 The blood glucose concentration should be measured in every case 
and hypoglycemia corrected if found. Similarly, hypokalemia should be 
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sought and, if clinically indicated, at least partially corrected; cardiac 
features have resolved in occasional patients on correction of potassium 
concentrations. It must be remembered, however, that the onset of 
acidosis, renal failure and cell damage may produce life-threatening 
hyperkalemia. Metabolic acidosis should be managed conventionally. 
Bicarbonate level less than 15 mEq/L requires bicarbonate in a dose of 
50-100 mEq intravenously every 8 hour 
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ECMO indications and procedure 
VA ECMO was considered for patients with AlP poisoning who 
were classified as high-risk group as defined below. 
 The patients of AlP poisoning were classified as a high risk if they 
met the following criteria: 
1. Left ventricular myocardial dysfunction i.e. EF of ≤35% 
2. Severe metabolic acidosis (pH ≤ 7.0) and/or refractory shock i.e. 
systolic blood pressure <80 mmHg despite conventional medical 
therapies. 
The cannulation site was determined based on patient status. The 
majority of patients underwent percutaneous cannulation through femoral 
vessels. The ECMO cannulation was done in intensive care unit. A 
venous cannula was placed in the inferior vena cava or right atrium for 
drainage infusion. The usual size of venous cannula ranges from 21 to 
25 F. The return cannula is a short arterial cannula inserted via the 
common femoral artery. This cannula is fully inserted to the taper, with 
the tip lying in the common iliac artery or lower aorta. The usual size of 
arterial cannula ranges from 17 to 21 F. Additional distal perfusion 9 F 
return cannula (“backflow cannula”) is inserted antegradely into the 
common femoral artery and directed into the superficial femoral artery. 
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The patients were maintained on a continuous heparin infusion to 
achieve an activated clotting time between 180 and 200 s. 
 The goal for the activated clotting time was adjusted if there were 
issues with bleeding or coagulation. To maintain a hemoglobin level of 
≥10 g/dL and a platelet count of ≥100,000 dL–1, patients received a 
transfusion during the ECMO treatment. 
 The patients were continuously monitored in terms of 
hemodynamic improvement, reversal of metabolic acidosis, and adequate 
oxygenation. Once these parameters are satisfactory, the ECMO weaning 
protocols were initiated. The circuit flow was reduced to assess the native 
cardiac function in the setting of an increased venous return. Flow was 
reduced from 2.5 L/min in a series of 0.5 L/min increments while 
hemodynamic and echocardiographic evaluations were done. 
 Decannulation was performed once the patient had improvement 
in LVEF to >35%, maintaining systolic blood pressure of >90 mmHg 
without any inotropic support and acidosis had recovered. 
 Venoarterial ECMO has shown promising improvement in the 
short-term survival of adults with AlP poisoning associated with LV 
dysfunction and severe metabolic acidosis and/or refractory shock.  
However, ECMO is also associated with significant complication 
rates. Another important highlight is the early presentation to the hospital 
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and immediate referral to the tertiary care center with facility and 
experience to use ECMO. The decision to start ECMO should be prompt. 
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TREATMENT OF COMPLICATIONS 
1 ) Hypoxia  
O2 inhalation, patent airway (endotracheal intubation and assisted 
ventilation, if necessary). Monitor blood gases.  
 
2) Shock  
Intravenous (IV) fluids (2 to 3 litres, out of which 50% should be 
saline) to be given during first 3 to 6 hours guided by central venous 
pressure or pulmonary capillary wedge pressure. Monitor electrolytes. 
Blood pressures should be monitored and kept above 80 mm Hg. Low-
dose of dopamine (2 to 4 µg/kg/min) and dobutamine (2.5 to 5 
µg/kg/min) may be used in combination to maintain renal perfusion.  IV 
hydrocortisone (200 to 400 mg) every 4 to 6 hours has been used to 
restore sensitivity to endogenous catecholamines.  
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3) Arrhythmias 
 Conventional antiarrhythmic drugs such as digoxin and xylocaine 
are ineffective. Others drugs being myocardial depressants are avoided 
but amiodarone has been used to combat fatal arrhythmias. Atropine has 
been found ineffective in bradyarrhythmias. 
 MgSO4 has also been found effective as a potent antiarrhythmic 
drug in the presence of hypoxia (anti-hypoxic effect), has been 
extensively used and found to be effective in certain arrhythmias. 
 
4) Metabolic acidosis 
 IV sodium bicarbonate to keep the HCO3– levels around 18 to 20 
mmol/L and pH >7.1. Dialysis is to be done if metabolic acidosis persists 
and patient is haemodynamically stable.  
 
5) Acute respiratory distress 
 Remove the patient to open air and loosen the clothes around the 
neck. To achieve PaO2 around 60% with distress syndrome lowest 
inspired fraction of O2 (FiO2), oxygen is delivered by simple face mask 
or face mask fitted with inspiratory (ARDS)/noncardiogenic reservoir 
bags at moderate flow rates (5 to 10 L/min of 100% O2). 
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 Mechanical support is indicated if above pulmonary oedema 
measures fail. Positive end expiratory pressure therapy may be tried to 
lower FiO2 below 0.6 provided patient is haemodynamically stable. 
Swan-Ganz catheter may be inserted for monitoring arterial and 
pulmonary wedge pressure, to measure cardiac output, fluid therapy, to 
monitor blood gas analysis and to guide diuretic therapy. 
6) Hypoglycaemia  
IV dextrose to combat hypoglycaemia which is reversible. 
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7) Hyperglycemia 
Treated with insulin along with other supportive measures to 
achive desired goal. 
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Presently the suggested measures include the following: 
           a. Management of circulatory shock with IV fluids (4 to 6 L over 6 
hours), while monitoring the central venous pressure and/or pulmonary 
wedge pressure. Dopamine can be given IV at a dose of 4 to 6 
mcg/kg/min (maximum 10 mcg/kg/min). 
           b. Management of respiratory distress with 100% humidified 
oxygen, intubation, and assisted ventilation. 
           c. Management of metabolic acidosis with sodium bicarbonate (50 
mEq/15 min) until the arterial bicarbonate rises above 15 mmol/L. 
           d. Control of convulsions with anticonvulsants (benzodaizepines, 
barbiturates, etc.). 
          e. Magnesium sulfate therapy*: Magnesium sulfate is said to be 
beneficial in the management of cardiac arrhythmias. Conventional 
antiarrhythmic drugs such as digoxin and lidocaine are ineffective.  
i. Magnesium sulfate is given IV as a 3 grams bolus, followed by 6 grams 
infusion over 24 hours for 5 to 7 days.  
 ii. Alternatively, 1 gram can be given IV to begin with, followed each 
hour by the same dose for 3 consecutive hours, and then 1 gram every 6 
hours for 5 days. 
 4. Ranitidine 50 mg IV 8th hourly to counter the severe epigastric pain. 
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MORTALITY 
Mortality is highly variable (37% to 100%) depending on the 
factors such as dose of the fresh pesticide consumed, early vomiting, 
duration and severity of poisoning, severity of shock and its response to 
resuscitative measures, etc. The most common cause of death is acute 
cardiovascular collapse followed by the development of ARDS. Early 
vomiting is the single factor that improves mortality. 
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POSTMORTEM FINDINGS 
     Postmortem findings include the viscerae to be heavy, 
oedematous and emitting foul smell. 
 The lungs show desquamated epithelium with alveoli thickened by 
haemolysed red blood cells and leucocytic infiltration around bronchioles 
The liver shows congestion, oedema, areas of centrizonal necrosis 
and mild-to-moderate fatty infiltration.  
The heart shows congestion, oedema, fragmented fibres, focal 
areas of myocardial necrosis and leucocytic infiltration.  
The kidneys show congestion, oedema, necrosis and degenerative 
and regenerative activity of the tubules.  
The stomach and the intestines also show congestion, oedema and 
leucocytic infiltration with sloughing of mucosa. 
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OBJECTIVES 
 
1.   To study the blood glucose levels in aluminium phosphide poisoning 
2.   To evaluate the role of hyperglycemia as a potential prognostic factor 
in acute aluminium phosphide poisoning 
 
SOURCE OY DATA 
The study will be conducted on 40 patients  admitted in 
Government Rajaji Hospital & Madurai Medical College during the study 
period from april 2017 to august 2017. 
 
INCLUSION  CRITERIA 
40 consecutive patients admitted with aluminium Phosphide Poisoning 
 
EXCLUSION  CRITERIA 
Known case of Diabetes Mellitus 
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DATA COLLECTION 
 
Informed consent will be obtained from all patients to be 
enrolled for the study. In all the patients relevant information will be 
collected in a predesigned proforma. 
The patients are selected based on clinical examinations, 
biochemical tests and History of aluminium Phosphide Poisoning. 
Patients were subjected to routine Investigations and Random 
Blood Sugar At the Time of admission. 
 
LABORATORY INVESTIGATIONS 
a) Complete blood count, 
b) Liver function test, 
c) Renal function test, 
d) Urine routine, 
e)      blood sugar on admission  
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DESIGN OF STUDY 
Prospective study. 
PERIOD OF STUDY 
6 MONTHS (may 2017 to august 2017) 
COLLABORATING DEPARTMENT 
DEPARTMENT OF BIOCHEMISTRY 
ETHICAL COMITTIE CLEARENCE : clearance applied 
CONSENT: Individual written and informed consent 
ANALYSIS: Statistical analysis 
CONFLICT OF INTEREST: Nil 
FINANCIAL SUPPORT: Self 
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RESULTS  
 
 
 
Gender No. (%) 
Male 34 (85.0) 
Female 6 (15.0) 
Total 40 (100.0) 
 
COMMENTS 
Among 40 patients, 34 were male patients and 6 were female 
patients in this study. 
85% 
15% 
Gender Distribution 
Male Female
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Age (in yrs) 
N 40 
Mean 35.5 
SD 10.6 
Minimum 19 
Maximum 61 
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Age group (in yrs) No. (%) 
≤30 14 (35.0) 
31 – 40 15 (37.5) 
41 – 50 7 (17.5) 
>50 4 (10.0) 
Total 40 (100.0) 
 
COMMENTS 
The mean age among the study population ( n= 40) is 35 yrs. The 
minimum age is 19yrs and maximum age included in study was 61yrs.  
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Random Blood 
Sugar – at the time 
of admission 
Outcome 
Death Survived 
No. (%) No. (%) 
<140 - 5 (83.3) 
≥140 34 (100.0) 1 (16.7) 
Total 34 (100.0) 6 (100.0) 
P value <0.001 
 
COMMENTS 
Among 40 patients, 34 patients died in this study. The random 
blood sugar at the time admission for those who died were found to have 
> 140 mg/dl. 6 patients were survived in this study and among them, the 
random blood sugar at admission was > 140 in 1 patient and < 140mg/dl 
in 5 patients. 
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Random Blood 
Sugar – at the time 
of admission 
Outcome 
Death Survived 
N 34 6 
Mean 184.5 114.3 
SD 35.2 41.0 
Minimum 144 68 
Maximum 285 184 
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COMMENTS 
The mean random blood sugar among patients who died was 184 
mg/dl and those who survived was 114mg/dl. This indicates that the 
elevated random blood sugar was a independent predictor of mortality in 
aluminium phosphide poisoning. 
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Correlation between Random Blood Sugar – at the time of admission 
and Duration of Hospital Stay 
 Mean 
Standard 
Deviation 
Correlation 
Co-efficient 
p-value 
Random Blood 
Sugar 
173.9 43.7 
-0.396 0.012 Duration of 
Hospital Stay 
(in hrs) 
78.7 70.3 
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ROC data 
Area under the ROC curve 0.907                                                         p=0.002 
RBS Sensitivity 95% CI Specificity 95% CI PPV 95% CI NPV 95% CI +LR -LR 
144.5 97.1 
84.1 – 
99.9 
83.3 
35.9 – 
99.6 
97.1 
84.6 – 
99.5 
83.3 
41.2 – 
97.3 
5.82 0.04 
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COMMENTS: 
Picture and table shows ROC curve and its relation to the  results. 
 
 
ROC Curve
1 - Specificity
1.00.75.50.250.00
S
en
si
ti
vi
ty
1.00
.75
.50
.25
0.00
72 
 
DISCUSSION 
Forty patients (06 women and 34 men) with AlP poisoning were 
included in the study. The mean age was 35.5 ± 10.6 years (range: 19–
61). 
 Most patients were in their second and third decade of life (Table 
1). Six patients survived (15%) and 34 patients expired (85%). AlP 
poisoning followed deliberate ingestion in all patients. 
 44.4% of patients were poisoned with only one tablet of AlP, 
delivering 1680 mg AlP. The interval time to treatment between ingestion 
and arrival at the hospital in survived and non-survived were 4.2 (±0.7) h 
and 2.8 (±0.3) h, respectively. There were no significant differences 
between survived and non-survived groups according to age, gender, and 
time to treatment.  
All patients required endotracheal intubation and mechanical 
ventilation. There was significant correlation between blood glucose level 
at the time of admission and outcome of the particular patient. 
The mean blood glucose levels in survived and expired patients 
were 114.3 ± 41.0 mg/dL and 184.5 ± 35.20 mg/dL, respectively , a 
difference that reached statistical significance (P = 0.001). thirty Six 
(85%) of nonsurvived and 06 (15%) of survived patients had blood 
glucose levels greater than 140 mg/dL. After adjusting according to age, 
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gender, ingested dose, pH, and HCO3. concentration, the odds ratio for 
hyperglycemia as a risk factor for death was 5.7 (CI 95% = 1.4–23.4).  
Several studies on the effect of aluminium phosphide poisoning on 
blood glucose levels have shown fluctuations in blood glucose levels. 
Following mechanisms are reported –  
 
1. Chugh, et al showed a significant rise in plasma cortisol( > 1048 
nmol/L) in 40% cases. Post mortem findings showed mild to 
moderate adrenal cortex changes. This involvement of adrenal axis 
provides an explanation for derangement in glucose homeostasis. 
2. In addition, this poisoning has been associated with acute 
pancreatitis lead on to hyperglycemia. 
3. AlP induce oxidative stress and increase extramitochondrial release 
of free oxygen radicals resulting in lipid peroxidation and protein 
denaturation of cellular membranes in various organs. 
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 The above mechanisms may explain the fact that hyperglycemia is 
a poor prognostic factor in aluminium phosphide poisoning. 
 The administration of Hyperinsulinemia euglycemia therapy has an 
advantage in improving mortality in AlP posoining. 
 It improves inotropy and peripheral vascular resistance and reverse 
acidosis by improving myocyte carbohydrate uptakeand utilisation. 
 Thus, oxidative stress can be possibly ameliorated by management 
of hyperglycemia and changes or disruptions in these mechanisms 
may reduce the risk of insulin resistance and the development of 
hyperglycemia and, furthermore, may have a potential role in its 
treatment 
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Previous research work has shown similar results. O Mehrpour et 
al., reported that non-survivors of AIP poisoning had a statistically 
significant tendency towards hyperglycemia when compared with 
survivors, suggesting that hyperglycemia may be used as a marker of AlP 
poisoning severity and may be a useful prognostic tool in evaluating and 
managing this particular poisoning.  
Hence, this study correlates the effect of hyperglycemia and 
mortality in aluminium phosphide poisoning and suggests that random 
blood glucose monitoring may be useful in guiding risk assessment and 
treatment of AIP poisoning. 
Insulin remains the obvious treatment for hyperglycaemia and 
lowering blood glucose levels to 80-110 mg/dl has a pivotal role in the 
treatment of such patients. Prevention of the inflammatory process and 
insulin resistance may also be important for the improvement of critically 
ill patients with acute hyperglycaemia. Although the role of treatment of 
hyperglycaemia with insulin and metformin has been evaluated in 
critically ill patients in the studies by Goldberg and Mojtahedzadeh, none 
of these modalities was performed in poisoning cases. A large 
randomized controlled trial study is necessary to affirm the role of insulin 
or metformin treatment in admission hyperglycaemia induced by severe 
poisoning. 
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Although poisoning cases with toxic agents which produce 
hypoglycaemia were excluded from our study, hypoglycaemia was also 
observed in some of the  patients. However, there was no relationship 
between hypoglycaemia and severity of poisoning. We have no 
explanation for this. Since hypoglycaemia recovered after 0.5-1 g/kg 
infusion of hypertonic dextrose, the poor nutrition of suicidal patients 
may be one of the reasons (because of an argument with their family they 
had not eaten lunch or dinner before the suicide attempt). 
In conclusion, acute poisoning-induced hyperglycaemia may be a 
good predictor of severity of poisoning and clinical outcome 
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CONCLUSION 
 
The importance of the findings of this study emphases on the 
significant negative effect of hyperglycemia on admission in patients with 
aluminium phosphide poisoning. The administration of Hyperinsulinemia 
euglycemia therapy has an advantage in improving mortality in AlP 
posoining. It improves inotropy and peripheral vascular resistance and 
reverse acidosis by improving myocyte carbohydrate uptakeand 
utilisation. Thus, oxidative stress can be possibly ameliorated by 
management of hyperglycemia and changes or disruptions in these 
mechanisms may reduce the risk of insulin resistance and the 
development of hyperglycemia and, furthermore, may have a potential 
role in its treatment. 
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      PROFORMA 
Name: 
Age / Sex: 
Occupation: 
Presenting complaints: 
Past History: 
H/o DM, HT, CKD, CVD, DRUG INTAKE, CAD, Thyroid 
disorders, Alcohol intake 
Clinical Examination: 
 
General Examination: 
Consciousness,  
Pallor,  
Jaundice,  
Clubbing,  
Lymphadenopathy,  
Hydration status 
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VITALS: 
PR 
BP 
RR 
SpO2 
 
SYSTEMIC EXAMINATION: 
 
CVS: 
 
RS: 
 
ABDOMEN 
 
CNS: 
 
Laboratory investigations: 
Random blood sugar at the time of admission 
1) Complete blood count 
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2) Renal function test 
3) Liver function test 
4) Urine routine 
5) Electrocardiogram 
6) Chest X ray 
7) USG abdomen 
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S.NO NAME AGE SEX DIAGNOSIS RANDOM BLOOD SUGAR AT OUTCOME DURATION OF HOSPITAL STAY
THE TIME OF ADMISSION
1 Murugesan 44 M Alumium Phophide Poisoning 150mgs% Death 2 days
2 Sathya 48 M Alumium Phophide Poisoning 184mgs% Survived 10 days
3 Ganesan 32 M Alumium Phophide Poisoning 155mgs% Death 5 days
4 raja 30 M Alumium Phophide Poisoning 204mgs% Death 16 Hours
5 sivaraman 32 M Alumium Phophide Poisoning 188mgs% Death 2 Days
6 bhuvana 25 F Alumium Phophide Poisoning 177mgs% Death 1 days
7 Arul 20 M Alumium Phophide Poisoning 148mgs% Death 5 days
8 Sangavi 21 F Alumium Phophide Poisoning 166mgs% Death 10 days
9 Ramasamy 25 M Alumium Phophide Poisoning 104mgs% Survived 6 days
10 Sampath 49 M Alumium Phophide Poisoning 135mgs% Survived 5 Days
11 christopher 40 M Alumium Phophide Poisoning 257mgs% Death 6 Hours
12 rani 45 F Alumium Phophide Poisoning 85mgs% Survived 5 Days
13 pandy 30 M Alumium Phophide Poisoning 147mgs% Death 2days
14 muthumeena 30 F Alumium Phophide Poisoning 144mgs% Death 7 Days
15 ananthi 30 F Alumium Phophide Poisoning 222mgs% Death 1 days
16 sumathi 32 F Alumium Phophide Poisoning 68mgs% Survived 3 Days
17 rajesh 44 M Alumium Phophide Poisoning 151mgs% Death 3 days
18 mani 61 M Alumium Phophide Poisoning 160mgs% Death 2 days
19 Murugesan 19 M Alumium Phophide Poisoning 166mgs% Death 3 days
20 palani 47 M Alumium Phophide Poisoning 198mgs% Death 1 days
21 kumar 40 M Alumium Phophide Poisoning 170mgs% Death 8 days
22 nallathambi 26 M Alumium Phophide Poisoning 180mgs% Death 7 Days
23 sivakumar 31 M Alumium Phophide Poisoning 221mgs% Death 12 Hours
24 muniyasamy 32 M Alumium Phophide Poisoning 200mgs% Death 10 Hours
25 mothilol 36 M Alumium Phophide Poisoning 168mgs% Death 4 Days
26 balu 39 M Alumium Phophide Poisoning 220mgs% Death 5 Hours
27 kannan 38 M Alumium Phophide Poisoning 180mgs% Death 10 days
28 rajendhiran 20 M Alumium Phophide Poisoning 188mgs% Death 1 days
29 thangapandy 29 M Alumium Phophide Poisoning 255mgs% Death 3 Hours
30 abbas 30 M Alumium Phophide Poisoning 210mgs% Death 5 Days
31 shyam 31 M Alumium Phophide Poisoning 155mgs% Death 1 days
32 naresh 34 M Alumium Phophide Poisoning 110mgs% Survived 4 Days
33 sampath 35 M Alumium Phophide Poisoning 145mgs% Death 2 days
34 perumal 36 M Alumium Phophide Poisoning 166mgs% Death 1 hours
35 kumeresan 52 M Alumium Phophide Poisoning 190mgs% Death 4 Days
36 karupaiah 61 M Alumium Phophide Poisoning 210mgs% Death 1 Days
37 dinesh 52 M Alumium Phophide Poisoning 147mgs% Death 6 days
38 hameed 36 M Alumium Phophide Poisoning 285mgs% Death 2 Hours
39 pandiyan 20 M Alumium Phophide Poisoning 155mgs% Death 2 Days
40 suresh 41 M Alumium Phophide Poisoning 195mgs% Death 1 Dyas
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